about
sameAs
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerGuidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Twenty years of anti-HER2 therapy-associated cardiotoxicityThreat posed by unproven drugs in medical oncologyTumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerThe Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.Hurdles and delays in access to anti-cancer drugs in Europe.Review: side effects of approved molecular targeted therapies in solid cancers.Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerGenome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsTargeted therapies in breast cancer: are heart and vessels also being targeted?Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available EvidenceAdjuvant chemotherapy in 2005: standards and beyond.Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation.Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.Trastuzumab (herceptin) for early-stage breast cancer.Molecular targeted therapies in breast cancer: where are we now?Trastuzumab for early breast cancer: current status and future directions.Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.Current perspectives of epothilones in breast cancer.Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceHER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.Facts and controversies in the use of trastuzumab in the adjuvant setting.
P50
Q26824542-8BCFCCAD-F75B-4ECE-A697-443926EEFD77Q27027579-EAC26538-DE2E-4F9B-AD41-99355B04D446Q27851705-09E6EBF6-80A6-48CB-ADD2-7AEC06AFBB5AQ28079391-FAE67F95-6D10-4D30-8394-E46C81AEE7C8Q29303933-01FDECAD-DE51-4EA3-B4C0-B5666ECAA264Q30234413-29F083DE-6E16-4EF3-AAA4-E843E0BB8D2BQ30758991-97774C16-1FDE-469B-87D3-31AA2BB940A5Q31130084-F488026D-3AD1-4D89-B93C-AE019D6548C1Q31159005-D425722D-645F-4B78-A329-08F1D14D1084Q33604264-F751A9A7-E129-4EBA-84C6-2D10E975D128Q34044771-573894CB-8F5C-46A0-9D0F-18C99CA180C0Q34206344-78AC4E8C-001A-49A9-B3D3-9E8CE7D32146Q34342897-F52DB367-223B-405E-8C8D-D17293336144Q34680656-504DD149-821E-492E-ADCC-03164770067CQ34731665-F9925ADD-248F-4D74-834E-B7E786A4D15AQ35947005-31E6CE21-1089-4B76-9E62-5BB3C6135790Q36084852-27F982C5-D660-4ABB-986F-CF818940F2D2Q36171157-D9082C45-5492-43C7-90AD-BA118D82373FQ36245324-00F7DDF9-DF9A-49BA-B3A9-07D61B295AA5Q36245341-CA747CEE-C170-4CB9-A9D7-64A2A1FC5925Q36248498-E572F29B-E2D4-4DE5-B978-590DCAA1A462Q36269780-8BBF870C-7DCD-4640-84E6-6C128B15D260Q36307517-62826491-10F7-4B84-8D9D-926AADE2F16AQ36311981-32986E9D-139A-419D-A157-0382407E3C9BQ36395909-73D41E84-E68F-49C0-B3AD-1FD0559D76B5Q36442804-715F5C9B-0A00-479D-BB7A-A2CEB5EE4268Q36490058-F7D46248-238D-47D1-B72D-E49E071E0581Q36630435-8A30386C-B1E6-401D-8204-491820B1D2BBQ36656902-C6EEF137-AC4E-4016-8460-8B23E1B3AA82Q36779175-4D93B8FB-E29F-4F53-A0D8-3B741145B3C5Q36826403-9B91FCC6-40C9-4E0C-BB51-04396F7E3F95Q36837565-A7948F79-A28B-4B21-8284-902E1E70AFE2Q36992945-3DF40BB7-5571-413F-924E-413CD3B74272Q37022428-C398067E-8FDE-4AC4-823D-AC1460DA7BB7Q37051869-4C0B2B2D-68E5-4BB4-9515-7F47F89CAF76Q37100311-E933C0F0-1D00-4F54-B4D9-53C878941DD9Q37184721-CD2C36BB-C031-4675-9BE3-0B6A4DC8D3D1Q37205521-7A2DCA97-BBB6-4BAA-BC86-168DA5260ED5Q37240710-261E3DD0-DE04-4ADC-AA50-CC5B15915319Q37263863-E0BF07E9-F4D2-42D4-B79A-4423FD2F508B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Evandro de Azambuja
@ast
Evandro de Azambuja
@en
Evandro de Azambuja
@es
Evandro de Azambuja
@nl
Evandro de Azambuja
@sl
type
label
Evandro de Azambuja
@ast
Evandro de Azambuja
@en
Evandro de Azambuja
@es
Evandro de Azambuja
@nl
Evandro de Azambuja
@sl
prefLabel
Evandro de Azambuja
@ast
Evandro de Azambuja
@en
Evandro de Azambuja
@es
Evandro de Azambuja
@nl
Evandro de Azambuja
@sl
P106
P1153
12446367900
P21
P31
P496
0000-0001-9501-4509
P569
2000-01-01T00:00:00Z